CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. However, real-world data on cladribine tablets are limited. CLICK-MS and MASTER-2 are single arm, observational, 30-month, Phase IV studies in the US evaluating the effectiveness and safety of cladribine tablets 3.5 mg/kg in patients with relapsing-remitting MS or active secondary progressive MS who had suboptimal response to prior injectable (CLICK-MS), or infusion/oral (MASTER-2) disease-modifying therapy. The primary end point is 24-month annualized relapse rate. Key secondary end points include patient-reported outcomes on quality of life measures, treatment adherence and adverse events. Studies began in 2019 and are expected to be completed in 2023. • CLICK-MS: NCT03933215 (ClinicalTrials.gov) ; adribine tablets: observational evaluation of effectveness and patient-reported outcomes in suboptimally ontrolled patients previously taing injectable disease-modifying drugs for relapsing forms of ultiple clerosis • MASTER-2: NCT03933202 (ClinicalTrials.gov) ; Cladribine tablets: observational evaluation of effectiveness and patient-reported outcomes in suboptilly controlled patient previously aking oral or infusion disase-modifying dugs for relapsing forms of multiple sclerosis.